volume 87, issue 2, P191-196 2009
DOI: 10.1038/clpt.2009.206
View full text
|
|
Share

Abstract: We aimed to assess the effect of coadministration and withdrawal of a potent cytochrome P450 3A (CYP3A) inhibitor (ritonavir) and a potent CYP3A inducer (St John's wort) on CYP3A enzyme activity in an open, fixed-sequence study design. We investigated the pharmacokinetics of midazolam: (i) at baseline, (ii) after a single dose of either St John's wort or ritonavir (each n = 6), (iii) after 14 days of coadministration of ritonavir (300 mg b.i.d.) and St John's wort (300 mg t.i.d.), and (iv) at 2 days after cess…

Expand abstract

Search citation statements

Order By: Relevance

Paper Sections

0
0
0
0
0

Citation Types

6
28
0

Publication Types

Select...

Relationship

0
0

Authors

Journals